NEW YORK – Myriad Genetics said on Tuesday after the close of the market that its revenues for the three months ended Dec. 31, 2020 declined 21 percent year over year.
Total revenues for the period were $154.6 million, down from $195.1 million. It beat the consensus Wall Street estimate of $150.4 million.
The Salt Lake City-based firm is in the process of changing its financial year to match the calendar year. It previously ended its fiscal year on June 30, but even with the change to match the calendar year, the company didn't report full-year financial results.